MX2022008949A - Formulacion de anticuerpos estable. - Google Patents
Formulacion de anticuerpos estable.Info
- Publication number
- MX2022008949A MX2022008949A MX2022008949A MX2022008949A MX2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- ebov
- present disclosure
- storage
- antibody formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965786P | 2020-01-24 | 2020-01-24 | |
| PCT/US2021/014524 WO2021150829A1 (en) | 2020-01-24 | 2021-01-22 | Stable antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008949A true MX2022008949A (es) | 2022-08-15 |
Family
ID=74858743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008949A MX2022008949A (es) | 2020-01-24 | 2021-01-22 | Formulacion de anticuerpos estable. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12337199B2 (https=) |
| EP (1) | EP4093435A1 (https=) |
| JP (2) | JP7674369B2 (https=) |
| KR (1) | KR20220131923A (https=) |
| CN (1) | CN115243718A (https=) |
| AU (1) | AU2021210942A1 (https=) |
| BR (1) | BR112022014240A2 (https=) |
| CA (1) | CA3162569A1 (https=) |
| CL (2) | CL2022001989A1 (https=) |
| CO (1) | CO2022010254A2 (https=) |
| IL (1) | IL294375B1 (https=) |
| MX (1) | MX2022008949A (https=) |
| WO (1) | WO2021150829A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| EP3487521A4 (en) | 2016-07-21 | 2020-07-01 | Emory University | ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM |
| KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| TW202529831A (zh) | 2023-10-02 | 2025-08-01 | 美商再生元醫藥公司 | 藥物遞輸裝置安全系統 |
| US12514939B2 (en) | 2024-02-14 | 2026-01-06 | Alpha-9 Oncology, Inc. | Stable radiopharmaceutical compositions and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US6630144B1 (en) | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| WO2009094755A1 (en) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| ES2676205T3 (es) * | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| JP6041580B2 (ja) * | 2012-08-28 | 2016-12-14 | 京セラ株式会社 | 電子機器、制御方法、及び制御プログラム |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| KR20210005096A (ko) * | 2018-04-25 | 2021-01-13 | 메디뮨 리미티드 | 인간 항-pd-l1 항체의 제형 |
-
2021
- 2021-01-22 IL IL294375A patent/IL294375B1/en unknown
- 2021-01-22 BR BR112022014240A patent/BR112022014240A2/pt unknown
- 2021-01-22 CA CA3162569A patent/CA3162569A1/en active Pending
- 2021-01-22 KR KR1020227025939A patent/KR20220131923A/ko active Pending
- 2021-01-22 US US17/155,432 patent/US12337199B2/en active Active
- 2021-01-22 WO PCT/US2021/014524 patent/WO2021150829A1/en not_active Ceased
- 2021-01-22 EP EP21710081.7A patent/EP4093435A1/en active Pending
- 2021-01-22 JP JP2022543445A patent/JP7674369B2/ja active Active
- 2021-01-22 MX MX2022008949A patent/MX2022008949A/es unknown
- 2021-01-22 CN CN202180010566.0A patent/CN115243718A/zh active Pending
- 2021-01-22 AU AU2021210942A patent/AU2021210942A1/en active Pending
-
2022
- 2022-07-20 CO CONC2022/0010254A patent/CO2022010254A2/es unknown
- 2022-07-22 CL CL2022001989A patent/CL2022001989A1/es unknown
-
2023
- 2023-08-30 CL CL2023002560A patent/CL2023002560A1/es unknown
-
2025
- 2025-03-10 JP JP2025037025A patent/JP2025090691A/ja active Pending
- 2025-05-20 US US19/213,776 patent/US20250288665A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220131923A (ko) | 2022-09-29 |
| CO2022010254A2 (es) | 2022-08-09 |
| IL294375B1 (en) | 2026-02-01 |
| CN115243718A (zh) | 2022-10-25 |
| JP2023511080A (ja) | 2023-03-16 |
| JP7674369B2 (ja) | 2025-05-09 |
| WO2021150829A1 (en) | 2021-07-29 |
| AU2021210942A1 (en) | 2022-07-14 |
| IL294375A (en) | 2022-08-01 |
| US12337199B2 (en) | 2025-06-24 |
| BR112022014240A2 (pt) | 2022-12-13 |
| JP2025090691A (ja) | 2025-06-17 |
| US20210252146A1 (en) | 2021-08-19 |
| CL2022001989A1 (es) | 2023-03-31 |
| CL2023002560A1 (es) | 2024-03-01 |
| CA3162569A1 (en) | 2021-07-29 |
| EP4093435A1 (en) | 2022-11-30 |
| US20250288665A1 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008949A (es) | Formulacion de anticuerpos estable. | |
| PH12019502123A1 (en) | Stable antibody formulation | |
| ES2537963T3 (es) | Estabilización de composiciones acuosas de proteínas con tampones de desplazamiento | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| PH12021552092A1 (en) | Stabilized formulations containing anti-il-33 antibodies | |
| MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| AU2013255457A8 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| TN2009000382A1 (en) | Stable antibody formulations | |
| WO2012076670A3 (en) | Antibody formulation | |
| MX360432B (es) | Formulaciones farmaceuticas muy concentradas. | |
| SA519402275B1 (ar) | تركيبة سائلة ثابتة تشتمل على ذيفان البوتولينوم | |
| MY205764A (en) | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex | |
| BR112021011290A2 (pt) | Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf | |
| ZA202204982B (en) | Stable formulation of integrin antibody | |
| BR112021019612A2 (pt) | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa | |
| EP4628092A8 (en) | Insulin aspart composition (embodiments) | |
| MX2022016218A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. | |
| CY1125584T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| MX2026001605A (es) | Proteinas modificadas | |
| TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |